Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for INVOKANA
- Renal Mechanism of SGLT2 Inhibition
- Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
- Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
- A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
- A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
- Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)
- Effects of Canagliflozin on Intravascular Volume and Hemodynamics
- Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
- Treatment of Diabetes in Patients With Systolic Heart Failure
- CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes
- Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan
- Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion
- TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.
- Canagliflozin-Mealtime Insulin Rescue
- The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin
- Pharmacogenetics of SGLT2 Inhibitors
- Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers
- Mechanisms of Weight Loss With SGLT2 Inhibition
- Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients
- Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants
- Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
- Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects
- A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers
Clinical trials list
click for details